Understanding the role of RBM39 in Acute Myeloid Leukemia and blood cell development
Dissecting the Roles and Requirements for RBM39 in Acute Myeloid Leukemia and Normal Hematopoiesis
This study is looking at how a protein called RBM39 affects the growth of blood cells and the development of Acute Myeloid Leukemia (AML), with the goal of finding new treatment options for patients with this type of cancer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10871868 on NIH RePORTER |
What this research studies
This research investigates how the RNA binding protein RBM39 affects both normal blood cell development and the progression of Acute Myeloid Leukemia (AML). By using advanced genetic screening techniques, the study aims to identify specific dependencies of AML on RBM39 and explore how certain mutations in RNA splicing factors make these cancers more vulnerable to targeted therapies. The research employs innovative mouse models to assess the role of RBM39 in leukemia initiation and maintenance, which could lead to new treatment strategies. Overall, this work seeks to deepen our understanding of cancer biology and improve therapeutic options for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia, particularly those with RNA splicing factor mutations.
Not a fit: Patients with other types of leukemia or those without RNA splicing factor mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Acute Myeloid Leukemia by targeting the RBM39 protein.
How similar studies have performed: Previous research has shown promising results in targeting RNA binding proteins in cancer, suggesting that this approach could be effective.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Lu, Sydney X — Stanford University
- Study coordinator: Lu, Sydney X
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.